Durysta, Latisse, Lumigan (bimatoprost) is a small molecule pharmaceutical. Bimatoprost was first approved as Durysta on 2001-03-16. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. The pharmaceutical is active against prostaglandin F2-alpha receptor. In addition, it is known to target aldo-keto reductase family 1 member C3. Latisse's patents are valid until 2034-10-31 (FDA).
|Indication||ocular hypertension, open-angle glaucoma|